{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:18:28Z","timestamp":1787797108857,"version":"build-2784847793"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,26]]},"DOI":"10.7759\/cureus.115260","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:54:46Z","timestamp":1787795686000},"source":"Crossref","is-referenced-by-count":0,"title":["Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis"],"prefix":"10.7759","author":[{"given":"Nassim","family":"Branine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff AM","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP, et al.. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med. 2023, 389:514-26. 10.1056\/NEJMoa2301972","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock J","year":"2023","unstructured":"Rosenstock J, Fr\u00edas JP, Jastreboff AM, et al.. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023, 402:529-44. 10.1016\/S0140-6736(23)01053-X","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)00967-0","article-title":"Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial","volume":"407","author":"Bajaj HS","year":"2026","unstructured":"Bajaj HS, Welch M, Shah P, et al.. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026, 407:2402-13. 10.1016\/S0140-6736(26)00967-0","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-017-0282-3","article-title":"Effects of Insulin plus glucagon-like peptide-1 receptor agonists (GLP-1RAs) in treating type 1 diabetes mellitus: a systematic review and meta-analysis","volume":"8","author":"Wang W","year":"2017","unstructured":"Wang W, Liu H, Xiao S, Liu S, Li X, Yu P. Effects of Insulin plus glucagon-like peptide-1 receptor agonists (GLP-1RAs) in treating type 1 diabetes mellitus: a systematic review and meta-analysis. Diabetes Ther. 2017, 8:727-38. 10.1007\/s13300-017-0282-3","journal-title":"Diabetes Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.975880","article-title":"Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus","volume":"14","author":"Tan X","year":"2023","unstructured":"Tan X, Pan X, Wu X, Zheng S, Chen Y, Liu D, Zhang X. Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus. Front Pharmacol. 2023, 14:975880. 10.3389\/fphar.2023.975880","journal-title":"Front Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-2379","article-title":"Tirzepatide in adults with type 1 diabetes: a Phase 2 randomized placebo-controlled clinical trial","volume":"49","author":"Snaith JR","year":"2026","unstructured":"Snaith JR, Frampton R, Samocha-Bonet D, Greenfield JR. Tirzepatide in adults with type 1 diabetes: a Phase 2 randomized placebo-controlled clinical trial. Diabetes Care. 2026, 49:161-70. 10.2337\/dc25-2379","journal-title":"Diabetes Care"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110925","article-title":"Incidence and characteristics of acute kidney injury in severe diabetic ketoacidosis","volume":"9","author":"Orban JC","year":"2014","unstructured":"Orban JC, Maizi\u00e8re EM, Ghaddab A, Van Obberghen E, Ichai C. Incidence and characteristics of acute kidney injury in severe diabetic ketoacidosis. PLoS One. 2014, 9:e110925. 10.1371\/journal.pone.0110925","journal-title":"PLoS One"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials","volume":"19","author":"Bettge K","year":"2017","unstructured":"Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab. 2017, 19:336-47. 10.1111\/dom.12824","journal-title":"Diabetes Obes Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos TD","year":"2014","unstructured":"Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2014, 11:202-30. 10.1900\/RDS.2014.11.202","journal-title":"Rev Diabet Stud"},{"key":"ref10","unstructured":"BMJ Best Practice. Shigella infection. (2026). Accessed: June 24, 2026: https:\/\/bestpractice.bmj.com\/topics\/en-gb\/1174."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics15172264","article-title":"Diagnostic evaluation of an increased risk of developing small intestinal bacterial overgrowth associated with glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1\/GIP receptor agonists: a global retrospective multicenter cohort analysis","volume":"15","author":"Sun Y","year":"2025","unstructured":"Sun Y, Veccia D, Liu BD, Tse W, Fass R, Song G. Diagnostic evaluation of an increased risk of developing small intestinal bacterial overgrowth associated with glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1\/GIP receptor agonists: a global retrospective multicenter cohort analysis. Diagnostics (Basel). 2025, 15:10.3390\/diagnostics15172264","journal-title":"Diagnostics (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1042\/bj2430039","article-title":"The rapid desensitization of glucagon-stimulated adenylate cyclase is a cyclic AMP-independent process that can be mimicked by hormones which stimulate inositol phospholipid metabolism","volume":"243","author":"Murphy GJ","year":"1987","unstructured":"Murphy GJ, Hruby VJ, Trivedi D, Wakelam MJ, Houslay MD. The rapid desensitization of glucagon-stimulated adenylate cyclase is a cyclic AMP-independent process that can be mimicked by hormones which stimulate inositol phospholipid metabolism. Biochem J. 1987, 243:39-46. 10.1042\/bj2430039","journal-title":"Biochem J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0754","article-title":"Effect of repeated glucagon doses on hepatic glycogen in type 1 diabetes: implications for a bihormonal closed-loop system","volume":"38","author":"Castle JR","year":"2015","unstructured":"Castle JR, El Youssef J, Bakhtiani PA, et al.. Effect of repeated glucagon doses on hepatic glycogen in type 1 diabetes: implications for a bihormonal closed-loop system. Diabetes Care. 2015, 38:2115-9. 10.2337\/dc15-0754","journal-title":"Diabetes Care"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/10600280241277551","article-title":"Bypassing prescribers and pharmacists: online purchasing of semaglutide and tirzepatide \u201cfor research purposes\u201d","volume":"59","author":"Belcourt J","year":"2025","unstructured":"Belcourt J, Ly P, White CM. Bypassing prescribers and pharmacists: online purchasing of semaglutide and tirzepatide \u201cfor research purposes\u201d. Ann Pharmacother. 2025, 59:485-90. 10.1177\/10600280241277551","journal-title":"Ann Pharmacother"},{"key":"ref15","unstructured":"MHRA urges public to avoid illegal online weight-loss medicines this new year. (2025). Accessed. June 24, 2026: https:\/\/www.gov.uk\/government\/news\/mhra-urges-public-to-avoid-illegal-online-weight-loss-medicines-this-new-year."},{"key":"ref16","unstructured":"FDA's concerns with unapproved GLP-1 drugs used for weight loss. (2026). Accessed. June 24, 2026: https:\/\/www.fda.gov\/drugs\/drug-alerts-and-statements\/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/526482-online-sourced-retatrutide-complicating-impending-diabetic-ketoacidosis-in-a-patient-with-type-1-diabetes-and-concurrent-shigella-gastroenteritis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T01:54:47Z","timestamp":1787795687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/526482-online-sourced-retatrutide-complicating-impending-diabetic-ketoacidosis-in-a-patient-with-type-1-diabetes-and-concurrent-shigella-gastroenteritis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.115260","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,26]]}}}